Aspira Pathlab & Diagnostics (540788.BO) Stock Price

Aspira Pathlab & Diagnostics Ltd generates revenue through pathology investigation services, radiology investigation services, and health packages at its diagnostic centers in Mumbai. The company offers specialized tests such as the Shanti Screening Test, COVID-19 Antibody Test, and COVID-19 RT-PCR Test, which are part of its diagnostic services portfolio. Customers include individuals seeking health screenings, patients requiring medical diagnostics, and healthcare providers who refer clients to its facilities. The firm's services are segmented into pathology, radiology, and health packages, with a focus on high-demand tests like COVID-19 detection profiles. The company's revenue streams are derived from conducting various pathological investigations across branches like biochemistry, hematology, and microbiology. Its health packages and pathology tests, including the COVID-19 Detection Profile 1 and 2, cater to both individual and institutional clients. The firm operates within the healthcare sector, providing diagnostic solutions for patients and medical professionals in Mumbai, with a particular emphasis on pandemic-related testing services during the global health crisis. Aspira Pathlab & Diagnostics Ltd monetizes its diagnostic capabilities through a mix of routine pathology services and specialized health packages. The Shanti Screening Test and other COVID-19-related tests form a significant portion of its revenue, especially during periods of high demand for pandemic testing. The company serves a broad customer base, including individuals, clinics, and hospitals that rely on its diagnostic expertise for accurate medical assessments.